![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland β April 3, 2024 β ObsEva SAΒ (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland β March 18, 2024 β ObsEva SAΒ (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, SwitzerlandΒ β 28 February 2024Β βΒ ObsEva SAΒ (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, SwitzerlandΒ β 31 January 2024Β βΒ ObsEva SAΒ (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, SwitzerlandΒ βΒ November 30, 2023Β βΒ ObsEva SAΒ (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Β Geneva, SwitzerlandΒ βΒ October 27, 2023Β βΒ ObsEva SAΒ (SIX: OBSN), a biopharmaceutical company developing novel therapies for...
ObsEva Files half Year 2023 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland β September 27, 2023 β ObsEva SA (SIX: OBSN), a...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, SwitzerlandΒ βΒ July 13, 2023Β βΒ ObsEva SAΒ (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, SwitzerlandΒ βΒ June 8, 2023Β βΒ ObsEva SAΒ (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Β GENEVA, Switzerland β May 2, 2023 β ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for womenβs...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | -2.4682 | -96.0389105058 | 2.57 | 3.35 | 0.08 | 2850489 | 0.46038868 | CS |
260 | -9.1682 | -98.9018338727 | 9.27 | 10.3504 | 0.08 | 2120527 | 1.71542025 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions